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ABSTRACT  26 
Background. Human cytomegalovirus (HCMV) is the leading cause of congenital infections 27 
resulting in severe morbidity and mortality among infected children. Although the virus is 28 
highly polymorphic, particularly in genes contributing to immune evasion, the mechanisms 29 
underlying its genetic variability and pathogenicity are only partially understood. 30 
Objectives. We aimed to characterize different HCMV clinical strains isolated from 21 31 
congenitally- or postnatally-infected children for in vitro growth properties and genetic 32 
polymorphisms.  33 
Study design. The growth of various HCMV isolates was analyzed in different cell culture 34 
models. Genetic polymorphism was assessed by genetic and phylogenetic analysis of viral 35 
genes involved in virulence (UL144, US28, and UL18), latency (UL133-138), or drug 36 
resistance (UL54 and UL97).  37 
Results. Here, we report a high degree of genetic and phenotypic diversity in distinct HCMV 38 
clinical isolates, as shown by their in vitro growth properties. In particular, HCMV isolates 39 
displayed the highest degree of genetic variability in the UL144 gene, where we were able to 40 
define four distinct genotypes within the cohort based on UL144 heterogeneity. Lastly, among 41 
all isolates we were able to identify 36 mutations in UL54 and 2 in UL97.  42 
Conclusions. Our findings indicate that surprisingly high levels of genetic HCMV variability 43 
correlate with a high degree of phenotypic polymorphism, which in turn might differentially 44 
influence the growth, fitness, and drug susceptibility of HCMV. 45 
 46 
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 HCMV clinical isolates possess different in vitro replication properties  52 
 They all share the same cell tropism, albeit showing different morphological patterns  53 
 For the most variable gene, UL144, four distinct genotypes were defined  54 
 In each HCMV isolate, we identified 36 mutations in UL54 and only 2 in UL97 55 




1. Background  57 
Human cytomegalovirus (HCMV), a double stranded DNA herpesvirus, is the most 58 
frequent cause of congenital malformations worldwide, resulting in neurodevelopmental delay, 59 
foetal or neonatal death, and most frequently sensorineural hearing loss [1–3]. It is 60 
characterized by a large genome encoding a wide range of gene products, endowed of effective 61 
immunomodulatory activity [4–6]. For instance, different viral genes encoding tumor necrosis 62 
factor-alpha (TNF-α) receptor (UL144), α-chemokines (UL146-147), β-chemokine receptor 63 
(US28) are potential virulence factors associated with severe congenital HCMV infection [7,8].  64 
Mounting evidence suggests that HCMV can be highly polymorphic, among and within 65 
hosts [9–13], with a high level of intrahost variability comparable to that of RNA viruses. It 66 
has been demonstrated that new mutations occur every time that the virus infects a new host, 67 
thereby giving rise to a unique viral strain for each infected individual. HCMV infection 68 
triggers indeed a selection event where a new genotype becomes dominant due to the selective 69 
pressure of the immune response [10]. Another possible explanation of this gap comes from 70 
the observation that both viral and host factors can contribute to the onset of HCMV genome 71 
mutations, thus fostering virus genetic drift during infection [14,15]. 72 
HCMV genetic variability, an emerging issue in drug resistance, represents another 73 
major obstacle on the way to predicting clinical outcomes of HCMV congenital infections. 74 
Currently, the only antiviral therapy available relies on nucleoside analogs, such as ganciclovir 75 
(GCV) and valganciclovir (VAL-GCV) [3,16]. In this regard, evidence from adult transplanted 76 
patients has shown that DNA polymerase (UL54) and viral phosphotransferase (UL97), two 77 
highly polymorphic HCMV genes, seem to play a role in drug resistance against GCV [17]. 78 
However, further research is clearly needed to fill the lack of information on congenitally 79 




2. Objectives 81 
Against this background, the aim of our study was to characterize the in vitro phenotype 82 
and the degree of genetic polymorphism of HCMV virions freshly isolated from congenitally 83 
or postnatally infected children, focusing on genes encoding potential virulence factors, such 84 
as UL144, US28, UL18, or contributing to viral latency, such as UL133-138. In addition to the 85 
aforementioned immunomodulatory genes, we also analyzed UL97 and UL54 to assess the 86 
emergence of drug resistant strains within the enrolled group of patients. Finally, we 87 
investigated a potential association between genotype and viral fitness. 88 
3. Study design  89 
3.1. Patients and samples 90 
Twenty-one children diagnosed with congenital or postnatal HCMV infection were 91 
recruited at the Neonatal Unit of the University of Turin from 2015 to 2017. Infection diagnosis 92 
was based on RT-PCR HCMV DNA detection in patients’ urine and blood samples. Urine 93 
samples were collected during the admission medical examination. The Neonatal Unit created 94 
a detailed database on clinical and pathological characteristics of recruited patients (indicated 95 
as P), summarized in Table 1. All patients were evaluated for neurobehavioral development, 96 
growth parameters, cerebral ultrasound, sight and hearing, antiviral and supportive therapy 97 
[18]. In addition, they were subjected to a follow up of one year of clinical and neurobehavioral 98 
tests for asymptomatic patients, and two years for symptomatic patients along with 6 years of 99 
audiology tests. 100 
3.2. Cells and viruses 101 
Primary human foreskin fibroblasts (HFF, American Type Culture Collection, ATCC 102 




human umbilical vein endothelial cells (HUVEC) were cultured as previously described [19]. 104 
For HFF infection with HCMV clinical isolates, urine samples were primarily inoculated in 105 
HFF in order to boost the infected cell population. The isolates were then propagated until 106 
approximately 60% of cells demonstrated a cytopathic effect. All isolates were used before 107 
passage 3 in order to avoid cell culture adaptation [20,21]. 108 
3.3. Viral replication analysis 109 
The replication of cell-associated isolates was quantified by focus expansion assay 110 
(FEA), as previously described [22]. Plaque area was calculated using ImageJ software. 111 
Statistical analysis was performed using GraphPad Prism version 5.00 for Windows. 112 
3.4. Immunofluorescence microscopy 113 
Indirect immunofluorescence analysis was performed at 72h pi as previously described 114 
[23]. The following primary antibodies were used: rabbit polyclonal anti-human von 115 
Willebrand factor (vWF) (Sigma-Aldrich), anti-IEA (immediate early antigen; produced in 116 
Santo Landolfo’s laboratory, University of Turin [24]), mouse monoclonal anti-IEA, UL44 117 
(Virusys Corporation), and pan cytokeratin (Sigma-Aldrich). Signals were detected using goat 118 
anti-rabbit or goat anti-mouse conjugated secondary antibodies (Life Technologies). Images 119 
were taken with a 40× objective by fluorescence microscope Olympus IX-70, equipped with 120 
cellSens Standard - Microscopy Imaging Software (Olympus), and ImageJ software was used 121 
for image processing.  122 
3.5. DNA sequencing 123 
Genomic DNA was extracted from infected cells by heating the cell with lysis buffer 124 
(1.25 M NaCl, 62 mM Tris-Cl pH 8.0, 9 mM EDTA pH 8.0, 0.5% SDS) for 15 min, followed 125 




High-Fidelity DNA Polymerase (New England BioLabs). Primers designed on human 127 
herpesvirus 5 strain Merlin sequence (NC_006273.2) and PCR conditions are listed in Table 128 
2. The amplified products were purified and used for Sanger sequencing (Eurofins Genomics).  129 
3.6. Phylogenetic analysis 130 
Nucleotide sequences were multiple-aligned to match homologue regions along Merlin 131 
reference genome (NC_006273) or along the most similar reference genomes. The alignment 132 
was performed using Clustal W, included into Geneious software 9.1, and each gene 133 
evolutionary model was selected using jModelTest 2.1.7 [25]. Gene sequences were 134 
concatenated, and the phylogenetic tree was reconstructed using a Bayesian approach 135 
(MrBayes 3.2.5) [26]. The tree was visualized with FigTree 1.4.2 software (Tree Figure 136 
Drawing Tool Version 1.4.2 2006-2014, University of Edinburgh). Robustness of the internal 137 
nodes was reported as a posterior probability calculated on the consensus of all the equally 138 
probable topologies obtained by the heuristic search. Recombination events were evaluated by 139 
using DualBrother plugin in Geneious software [27], SpliTree [28] and SimPlot [29], 140 
considering both single genes and concatenated alignments. Association between concatenated 141 
tree topology and clinical parameters was investigated using BaTS algorithms evaluating 142 
Association Index (AI), Parsimony score (PS) and monophyletic clade (MC) size statistics. 143 
3.7 Identification of mutations associated with antiviral drug susceptibility in HCMV clinical 144 
strains 145 
To ascertain whether the in vitro growth variability of HCMV clinical isolates 146 
correlated with different degrees of drug susceptibility, we used the web-based search tool 147 
mutation resistance analyzer (MRA) is a platform linking identified HCMV drug resistance 148 
mutations to specific phenotypes (http://www.informatik.uni-149 




regularly updated database containing previously published UL97 and UL54 mutations and the 151 
corresponding in vitro drug susceptibility phenotypes. 152 
4. Results 153 
4.1. Phenotypic characterization of HCMV clinical strains  154 
First, we carried out phenotypic characterization of HCMV isolates from all patients 155 
(P), with the exception of P13 and P19, in HFF. Interestingly, we observed a remarkable 156 
variation of fibroblast growth properties among the various isolates, with a high value range of 157 
infected foci per well (Table 3).  158 
Since cell-free virus transmission is typified by a comet tail phenotype, while cell-159 
associated transmission is characterized by plaques with well-defined edges [22], we sought to 160 
determine the transmission pattern of different HCMV clinical isolates by defining plaque 161 
morphology. Furthermore, to quantify HCMV replication, we calculated the relative plaque 162 
area in HCMV infected HFF. We found that among all isolates, P14 and P15 were those 163 
displaying the most aggressive/fast-replicative behavior (Fig. 1A upper panel). These results 164 
were also supported by virus plaque morphology analysis showing that P14 displayed larger 165 
and comet shaped plaques compared to P9 (Fig. 1A, lower panel). We observed the same 166 
infection pattern in HUVEC and ARPE-19 (Fig. 1B and C). Accordingly, in these two cell 167 
lines, plaque morphology and area analysis revealed a great heterogeneity (Figure 1B, C) even 168 
though the extent of viral growth in HFF did not exactly mirror that seen in HUVEC and ARPE-169 
19. Indeed, in HUVEC P12 and P18 showed a statistically significant larger plaque area 170 
compared to that of P9, albeit to a lower extent with respect to P14 and P15, indicating that 171 





Fig. 1. Replication properties of HCMV clinical isolates. Viral replication was analyzed by focus 174 
expansion assay (FEA). Serial dilutions of HFF (A), HUVEC (B), and ARPE-19 (C) infected by clinical 175 
isolates were cocultured with an excess of uninfected HFF for 5 days. Monolayers were then fixed, and 176 
infected cells were traced by antibodies against HCMV immediate early antigen (IEA), followed by 177 
immunoperoxidase assay. Infectious foci were defined as clusters of at least three infected cells, starting 178 
from single late-stage infected cells. Upper panel. Plaque areas were calculated using ImageJ software. 179 
The red bars represent mean values. Differences were considered statistically significant for *, P< 0.05; 180 
**, P< 0.01; ***, P< 0.001 (one-way ANOVA followed by Bonferroni’s post-tests, GraphPad Prism 181 
version 5.00 for Windows, for comparison of all isolates versus P9). Lower panel. Representative 182 
infectious foci of clinical isolates 9 (P9) and 14 (P14) are shown.  183 
4.2. Definition of the endothelio- and epithelio-tropic phenotype of different HCMV isolates 184 
Next, we assessed HCMV isolates for viral growth. The FEA in HUVEC and ARPE-185 
19 revealed that all isolates retained their endothelial and epithelial tropism (Fig. 1 B, C). To 186 
rule out the possibility that inoculated infected HFF could overgrow to form infected foci 187 




Willebrand factor (vWF) and pan cytokeratin (Fig. 2 A and B). Based on HCMV 189 
aggressiveness, epithelial cell infection resulted in two distinct morphological phenotypes (Fig. 190 
2). Whereas fast-replicative isolates, such as P14, formed enlarged flower-shaped syncytial 191 
foci, slow-replicative isolates, such as P9, were only visible as single mononucleated infected 192 
cells (Fig. 2A). These dual phenotypes were not observed in HUVEC, suggesting a distinct 193 
replication pattern among different cell lines and viral isolates (Fig. 2B).  194 
 195 
Fig. 2. Definition of the endothelio- and epithelio-tropic phenotype of different HCMV clinical 196 
isolates. ARPE-19 (A) and HUVEC (B) were cocultured with an excess of HFF infected with 197 
representative HCMV clinical isolates (P9 and P14) or mock infected. Cells were fixed 72 h later for 198 
immunofluorescence analysis to detect HCMV immediate early antigen IEA (red) and the inherent cell 199 




4',6-diamidino-2-phenylindole (DAPI) (blue). Images were taken with a 40× objective by fluorescence 201 
microscopy. The most representative infectious foci are shown. 202 
4.3. Genetic characterization of HCMV clinical strains 203 
To determine whether phenotypic changes were accompanied by alterations at the DNA 204 
level, we performed comparative analysis of a set of genes encoding potential virulence factors 205 
(i.e. UL144, US28, UL18), or contributing to viral latency (i.e. UL133-138), or associated with 206 
drug resistance (i.e. UL54, UL97) (Table 2). For each region/gene, the sequences were aligned 207 
and, based on the best GTR+ evolutionary models, the Bayesian trees were drawn (Fig. S1-208 
S6). Given that HCMV often shows recombination events [31], the alignment was used to 209 
create a split network (Fig. 3A), and a set of reference sequences was included. Statistically 210 
significant evidence of recombination was identified along the concatenated alignment ( p < 211 
0.05) (Fig. 3A). Moreover, the SimPlot showed a great heterogeneity (Fig. 3B), reaching the 212 
highest variability within the UL144 gene (Fig. 3C), found exclusively in clinical HCMV 213 
strains.  214 
Remarkably, UL144 amino acid sequence alignment from all HCMV isolates defined 215 
four prevalent subgenotypes, namely A, B, C, and A/B (Fig. 4B). The majority of sequences 216 
matched with genotype B, whereas those from the isolates P1, P12, and P20, closely related to 217 
the Merlin reference strain, were classified under genotype A. Furthermore, sequences derived 218 
from the P5, P18 and P21 isolates matched with genotype C, whereas only the P3-derived 219 
amino acid sequence was listed under genotype A/B. Interestingly, we noticed that both the 220 
P14 and P15 fast-replicative strains belonged to genotype B, indicating that the viral genetic 221 
background can indeed determine viral fitness.  222 
Noteworthy, considering both nucleotide (Fig. 3C) and amino acid sequences (Fig. 4A), 223 




discriminate the four genotypes. However, despite having a different genotype, we observed 225 
that almost all cysteines were conserved along the alignment, suggesting that distinct HCMV 226 
isolates may share a similar viral protein folding.  227 
Finally, no statistically significant associations were found between the concatenated 228 
tree topology and any clinical parameter reported in Table 1, considering both global (AI and 229 
PS) and local (MCs) association parameters. 230 
GenBank accession numbers of all sequences are reported in Table S1. 231 
 232 
Fig. 3. Genetic analyses on HCMV clinical isolates. (A) Split network; (B) SimPlot of concatenated 233 
alignment; (C) SimPlot of UL144 alignment; mean nucleotide diversity among samples = 86.59% 234 





Fig. 4. UL144 gene analysis. Amino acid alignment (A) and neighbor joining tree (B), based on amino 237 
acidic sequence alignment, are reported. Dots indicate identical residue. Genotypes are indicated for 238 
each tree clade.  239 
4.4. Antiviral drug susceptibility of HCMV clinical strains 240 
 Complete sequences of UL54 and UL97 from HCMV isolates were uploaded in MRA 241 
and compared to the wild-type sequence of the drug-sensitive HCMV strain TB40-BAC4 242 
[32,33]. MRA identified 36 mutations in the UL54 gene associated with genetic polymorphism 243 
previously published [34–39], whereas only two mutations were detected in UL97, probably 244 




Interestingly, drug resistance-associated mutations varied among patients, especially in 246 
UL54 and to a lesser extent in UL97 (Figure 5A and B). 247 
 248 
Fig. 5. Antiviral susceptibility testing. The heterogeneity of UL54 (A) and UL97 (B) genes is reported. 249 
Left panel. The heat maps show the presence and the positions of amino acidic changes, and the 250 
histograms show the frequency of each modification. Right panel. The Bayesian tree describes the 251 




5. Discussion  253 
The clinical and biological relevance of HCMV genetic variability in congenitally and 254 
postnatally infected children has been the focus of intense research over the past few years. In 255 
this study, we sought to determine whether and to what extent the differences in gene 256 
composition affected viral fitness. For this purpose, we enrolled 21 pediatric patients with 257 
confirmed congenital or postnatal HCMV infection. We evaluated the degree of genetic 258 
polymorphism of HCMV clinical strains by genetic and phylogenetic analyses, primarily 259 
focusing on viral genes involved in virulence, latency, and drug resistance. In parallel, we ran 260 
an extensive in vitro analysis of all clinical isolates to characterize viral growth properties and 261 
viral tropism in fibroblasts, endothelial and epithelial cells. Our results suggest that HCMV 262 
clinical isolates possess phenotypic differences as judged by both viral dissemination rate and 263 
replication properties, which define the extent of strain aggressiveness. Particularly, the two 264 
strains P14 and P15 were the most aggressive and fast-replicative ones because they could give 265 
rise to infectious foci characterized by comet-shaped plaques, typically observed in laboratory 266 
strains [22]. Altogether, these results support the hypothesis that HCMV heterogeneity may 267 
have an impact on viral fitness, influencing both viral dissemination rate and replication 268 
properties.  269 
The reliability of such results could be inferred from the different cell lines employed 270 
for virus propagation and their low passage number (≤ 3) to ensure that no cell-culture 271 
adaptation had occurred [20,21]. All clinical isolates in the recruited group of patients were 272 
able to infect both epithelial and endothelial cells displaying no difference in their cell tropism, 273 
while they displayed a unique morphological pattern in cells infected with fast-replicative 274 
isolates. Interestingly, the enlarged flower-shaped syncytial foci typical of epithelial, but not 275 
endothelial, cells obtained with the most aggressive strains were similar to those observed by 276 




chromosome (ΔUL96BAC) [44], which could be partly ascribed to different maturation 278 
patterns between isolates. 279 
The analysis of specific HCMV genome regions suggests that genetic variability among 280 
HCMV isolates may impact viral fitness. Indeed, here we report enhanced sequence diversity, 281 
identified thanks to the 5’ region of UL144 alignment used as a discriminatory criterion. 282 
Interestingly, the high degree of nucleotide heterogeneity mirrors in the amino acidic sequence, 283 
indicating a considerable difference among UL144 genotypes. This is interesting, as UL144 is 284 
a potent NF-κB activator [45] that plays a role in virus-mediated immune evasion [46,47]. This 285 
high heterogeneity of UL144 strongly influenced the split tree configuration based on the 286 
concatenated alignment, highlighting the role of this gene in the description of genetic 287 
relationships between CMV isolates. The same sample clustering has been demonstrated for 288 
both UL54 and UL97 genes, known to be involved in antiviral drug resistance. In both cases, 289 
the similarity among samples was high even though a number of previously reported mutations 290 
were identified in UL54 and to a lower extent in UL97. However, all treated patients so far 291 
responded to valganciclovir therapy. Nonetheless, we are not able to fully exclude the 292 
possibility that the reported mutations might have an impact on the antiviral therapy over a 293 
prolonged time. 294 
It is highly likely that multiple strains of CMV are present in each patient of our group 295 
of patients, similar to cases being previously extensively reported in the literature [12]. 296 
However, we used an approach based on the Sanger sequencing of PCR products obtained from 297 
cell culture. The sensitivity of this method is strongly dependent on the relative frequency of 298 
viral variants. In particular, low-abundance viral populations are likely to be missed and the 299 
overall viral diversity to be underestimated. Thus, although sequence electropherograms did 300 
not show clear evidence of multiple signals (i.e., double peaks and/or high background signal), 301 




to evaluate the role of mixed infections in pediatric infected patients, including PCR product 303 
cloning strategies or next generation sequencing approaches. 304 
The limits of our study include the small number of the recruited patients, the short 305 
collection period (two years) in the limited geographic area. Besides, not all the analysis were 306 
available for all the samples, f.i. propagation and isolation of the virus failed for P13 307 
(simultaneous presence of pathogenic bacteria and yeast in the patient’s urine, since patient 13 308 
was presented with severe sepsis at admission) and P19 (low viral load in urine sample). 309 
In conclusion, our study may suggest that genotypic variability is associated with in 310 
vitro phenotypic diversity in HCMV clinical strains isolated from a group of congenitally and 311 
postnatally infected patients. In addition, our results indicate that genetic polymorphisms 312 
across the UL54 genome might play a role in multidrug resistance HCMV infection, pointing 313 
to UL54 as a potential therapeutic target to consider when treating congenital HCMV disease. 314 
This is, to our knowledge, the first detailed analysis that tries to associate in the same cohort of 315 
patients’ genetic polymorphism and viral fitness. Although the results achieved so far do not 316 
allow any definitive conclusion, it emerges that a strong genetic HCMV variability is reflected 317 
in a remarkable phenotypic polymorphism that could affect virus growth properties and in vivo 318 
fitness.  319 
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pregnancy 
















9.5% 3rd 19.1% Pos 0% 
















Birth weight (0=≥10°pc;  
1=3-10 pc; 2=≤3°pc) 
Head circumference 
(0= ≥10°pc/ 1=<10°pc) 
Children age 
at time of sampling  











N/A 9.5% N/A 9.5% 






Cerebral MRd or 
CTe,c 
Plateletsc Neutrophilsc Hepatic functionalityc 
0 76.2% 0 52.3% 0 38% 0 
80.9
% 
0 76.2% 0 71.4% 
1 14.3% 1 42.9% 1 28.6% 1 4.8% 1 9.5% 1 9.5% 
N/A 9.5% N/A 4.8% N/A 33.4% N/A 
14.3
% 
N/A 14.3% N/A 19.1% 
VIRAL LOAD ANTIVIRAL THERAPY 
Viral load (urine) Viral load (blood) 
Valganciclovir (os) 
at time of sampling 
Valganciclovir (os) 
after sampling 
Neg 0% Neg 4.8% 
4.8% 14.3% 
Pos 100% Pos 66.7% 










aIUGR: intrauterine growth restriction; bN/A: not available; c0: normal, 1: pathologic; dMR: magnetic 513 
resonance; eCT: computed tomography; fabnormal laboratory indicators: platelet count < 100,000/mm3, 514 
neutrophils count < 1,000/mm3, ALAT > 80 IU/l, conjugated bilirubin plasma level > 2 mg/dl and > 515 
10% of total bilirubin, per os: oral administration. 516 
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Table 3. Growth properties of HCMV clinical isolates.  521 
Patients’ 
code 
Mean No. of IEA positive foci/infected cell dilution 
HFF HUVEC ARPE-19 
P1 8*102 5*103 4*102 
P2 6*102 1*103 5*103 
P3 2*102 1*103 7*103 
P4 3*102 3*103 2*102 
P5 5*102 2*103 3*102 
P6 7*102 1*102 7*103 
P7 2*102 1*102 3*102 
P8 7*102 1*103 1*102 
P9 2*102 1*105 8*104 
P10 1*103 1*103 6*103 
P11 4*103 3*104 3*102 
P12 9*103 1.3*104 1*101 
P14 3*101 1*102 1*102 
P15 6*102 2*102 3*102 
P16 5*102 1*101 1*102 
P17 1.9*104 2.2*105 4.4*105 
P18 4*104 2.7*105 7.9*105 
P20 4*103 5*103 7*103 
P21 9*102 5*102 1*102 
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